Publisher's Synopsis
This is a compendium of 730 individual monographs on the most important drugs in use around the world. Written by clinicians who actually use the drugs, and subsequently edited by specialists in various aspects of pharmacology, the volume is an up-to-date source of reference for clinicians and clinical pharmacologists.;The information is clearly laid out and in most cases includes a diagram of the chemistry and/or metabolism of the relevant drug. Each of the monographs conforms to standard headings which range from detailed information on its chemistry, pharmacology, metabolism, therapeutic use and toxicology to clinical information not so readily available in other drug compendiums. Indications and contraindications, adverse reactions, use by high risk groups and drug interactions are among the other standard headings.;The specialist international contributors have been invited to compose a monograph or monographs only on drugs with which they have a lot of contact so there is a large degree of specialized knowledge.;There are three indexes: a name index providing an alphabetical listing of all the drugs covered by the non-proprietary, proprietary and chemical name; a therapeutic use index which lists monographs under major divisions of therapeutic use eg anaesthesia, as well as all main body systems and / or organs eg cardiovascular system; and a drug type index which lists drugs according to the pharmacological mechanism of action of the drug.;Additionally, referencing of each monograph makes an even larger pool of information available to the reader.;TThe "First Supplement" adds 30 to 40 new monographs to those already published in "Therapeutic Drugs". The drugs covered include: adenosine, almitrine, alprazolam, amoxapine, apomorphin, azithromycin, benazepril, buproprion, calcipotriol, carvedilol, catreolol, centoxin, cetirizine, cilazapril, cisapride, clairithromycin.;The supplement also contains other information. Some drugs have been withdrawn from the market for reasons of toxicity and the adverse effects which have led to the removal of the drug from sale are described.
